Insider Sale: Chief Medical Officer of $MGX Sells 5,239 Shares
Insider Trading Activity: Sarah B. Noonberg, Chief Medical Officer of $MGX, sold 5,239 shares on June 6, 2025, representing about 4.6% of her holdings, leaving her with 109,135 shares. In the past six months, all insider trades for $MGX have been sales, totaling six transactions.
Institutional and Analyst Insights: Recent data shows that 38 institutional investors increased their positions in $MGX while 39 decreased theirs. Analysts have issued one buy rating and no sell ratings for the stock in recent months.
Trade with 70% Backtested Accuracy
Analyst Views on MGX
About MGX
About the author
Metagenomi Therapeutics Renames Company, Plans IND Submission for MGX-001 in 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic focus on late-stage preclinical assets, aiming to leverage its advanced gene-editing capabilities to drive the success of therapeutic programs, particularly in hemophilia A.
- Clinical Advancement: MGX-001 has demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, with plans to submit IND/CTA in Q4 2026 and initiate first-in-human studies in 2027.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring financial stability while advancing MGX-001 and other therapeutic projects, thereby enhancing investor confidence.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other potential therapies, showcasing its strong competitiveness and market potential in the gene therapy sector.
Metagenomi Therapeutics Renames to Reflect Focus on Gene Therapy, MGX-001 IND Submission Planned for 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic evolution focused on late-stage preclinical assets, particularly the MGX-001 program for hemophilia A, which is expected to submit IND/CTA in 2026, marking a significant advancement in gene therapy.
- Clinical Readiness: MGX-001 demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, supporting its potential as a best-in-class treatment, with plans to initiate first-in-human studies in 2027 to further advance clinical development.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring sufficient funding to support the advancement of MGX-001 and other therapeutic projects, thereby enhancing its competitive position in the market.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other secreted protein deficiencies, showcasing the company's strong technological capabilities and promising market outlook in the field of gene editing.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
Amazon's Custom Chips Present a New Challenge for Nvidia
Amazon's New AI Chip: Amazon Web Services has launched its Trainium3 custom AI chip, which is claimed to be four times faster than its previous AI chips.
Cost Efficiency: The Trainium3 chip can potentially reduce the costs of training and operating AI models by up to 50% compared to systems using equivalent GPUs.
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
BioAtla Inc. Gains: BioAtla's shares surged 13.94% in after-hours trading, attributed to investor reactions to recent financing agreements, despite no new company-specific news.
Metagenomi Inc. and PAVmed Inc. Movements: Metagenomi's stock rose 5.71% with no new updates, while PAVmed advanced 5.72% after reporting a significant net loss and a sharp decline in revenue.
Precision BioSciences' Positive Outlook: Precision BioSciences gained 2.94% after announcing it will present Phase 1 trial data at an upcoming conference, boosting investor optimism.
Entero Therapeutics Rebranding: Entero Therapeutics' shares increased 3.68% following its announcement of a rebranding to GridAI Technologies Corp., effective December 1, 2025, along with a new ticker symbol.
Metagenomi (MGX) Posts Q3 Loss, Falls Short of Revenue Projections
Quarterly Performance: Metagenomi reported a quarterly loss of $0.55 per share, slightly better than the expected loss of $0.60, but worse than a loss of $0.45 per share a year ago. The company also posted revenues of $8.66 million, missing estimates by 6.44%.
Stock Performance: Metagenomi shares have declined by approximately 40.4% since the start of the year, contrasting with a 16.2% gain in the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Outlook: The consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $9.26 million, while the fiscal year estimate is -$2.39 on $30.44 million in revenues. The mixed trend in earnings estimate revisions could influence future stock performance.
Industry Context: The Medical - Drugs industry, to which Metagenomi belongs, is currently ranked in the top 33% of Zacks industries, suggesting a favorable environment for stocks in this sector. Another company in the same industry, Nutriband Inc., is expected to report a significant loss in its upcoming results.
Metagenomi Therapeutics Renames Company, Plans IND Submission for MGX-001 in 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic focus on late-stage preclinical assets, aiming to leverage its advanced gene-editing capabilities to drive the success of therapeutic programs, particularly in hemophilia A.
- Clinical Advancement: MGX-001 has demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, with plans to submit IND/CTA in Q4 2026 and initiate first-in-human studies in 2027.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring financial stability while advancing MGX-001 and other therapeutic projects, thereby enhancing investor confidence.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other potential therapies, showcasing its strong competitiveness and market potential in the gene therapy sector.
Metagenomi Therapeutics Renames to Reflect Focus on Gene Therapy, MGX-001 IND Submission Planned for 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic evolution focused on late-stage preclinical assets, particularly the MGX-001 program for hemophilia A, which is expected to submit IND/CTA in 2026, marking a significant advancement in gene therapy.
- Clinical Readiness: MGX-001 demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, supporting its potential as a best-in-class treatment, with plans to initiate first-in-human studies in 2027 to further advance clinical development.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring sufficient funding to support the advancement of MGX-001 and other therapeutic projects, thereby enhancing its competitive position in the market.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other secreted protein deficiencies, showcasing the company's strong technological capabilities and promising market outlook in the field of gene editing.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
Amazon's Custom Chips Present a New Challenge for Nvidia
Amazon's New AI Chip: Amazon Web Services has launched its Trainium3 custom AI chip, which is claimed to be four times faster than its previous AI chips.
Cost Efficiency: The Trainium3 chip can potentially reduce the costs of training and operating AI models by up to 50% compared to systems using equivalent GPUs.
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
BioAtla Inc. Gains: BioAtla's shares surged 13.94% in after-hours trading, attributed to investor reactions to recent financing agreements, despite no new company-specific news.
Metagenomi Inc. and PAVmed Inc. Movements: Metagenomi's stock rose 5.71% with no new updates, while PAVmed advanced 5.72% after reporting a significant net loss and a sharp decline in revenue.
Precision BioSciences' Positive Outlook: Precision BioSciences gained 2.94% after announcing it will present Phase 1 trial data at an upcoming conference, boosting investor optimism.
Entero Therapeutics Rebranding: Entero Therapeutics' shares increased 3.68% following its announcement of a rebranding to GridAI Technologies Corp., effective December 1, 2025, along with a new ticker symbol.
Metagenomi (MGX) Posts Q3 Loss, Falls Short of Revenue Projections
Quarterly Performance: Metagenomi reported a quarterly loss of $0.55 per share, slightly better than the expected loss of $0.60, but worse than a loss of $0.45 per share a year ago. The company also posted revenues of $8.66 million, missing estimates by 6.44%.
Stock Performance: Metagenomi shares have declined by approximately 40.4% since the start of the year, contrasting with a 16.2% gain in the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Outlook: The consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $9.26 million, while the fiscal year estimate is -$2.39 on $30.44 million in revenues. The mixed trend in earnings estimate revisions could influence future stock performance.
Industry Context: The Medical - Drugs industry, to which Metagenomi belongs, is currently ranked in the top 33% of Zacks industries, suggesting a favorable environment for stocks in this sector. Another company in the same industry, Nutriband Inc., is expected to report a significant loss in its upcoming results.
